Insider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now directly owns 250,713 shares in the company, valued at approximately $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Allogene Therapeutics Price Performance

ALLO stock opened at $1.51 on Friday. Allogene Therapeutics, Inc. has a 1-year low of $1.50 and a 1-year high of $5.78. The business has a 50 day simple moving average of $2.01 and a two-hundred day simple moving average of $2.43. The company has a market capitalization of $316.60 million, a price-to-earnings ratio of -0.97 and a beta of 0.83.

Hedge Funds Weigh In On Allogene Therapeutics

Several hedge funds have recently modified their holdings of the stock. Barclays PLC increased its holdings in Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after acquiring an additional 172,745 shares during the last quarter. Zacks Investment Management purchased a new position in shares of Allogene Therapeutics during the third quarter valued at about $1,446,000. Geode Capital Management LLC grew its position in shares of Allogene Therapeutics by 14.4% during the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after purchasing an additional 407,070 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Allogene Therapeutics by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after purchasing an additional 507,021 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Allogene Therapeutics by 70.3% in the second quarter. The Manufacturers Life Insurance Company now owns 480,381 shares of the company’s stock worth $1,119,000 after buying an additional 198,231 shares in the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Wall Street Analyst Weigh In

ALLO has been the subject of a number of analyst reports. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a research note on Friday, November 8th. Finally, Piper Sandler decreased their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).